ArticleStem cells (Dayton, Ohio)2017
A Glycovariant of Human CD44 is Characteristically Expressed on Human Mesenchymal Stem Cells.
Article in Stem cells (Dayton, Ohio), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Encoding Cell-Surface Receptor Function Through Glycosylation: Lessons From CD44.Chembiochem : a European journal of chemical biology · 2026Review
- Targeting single-cell multiomics-identified vascular impairment:Materials today. Bio · 2026Article
- Functionally Distinct Shed Subpopulations Detected After Magnetic-Activated Cell Sorting of CD71 and CD146.Cells · 2025Article
- Human umbilical cord mesenchymal stem cells attenuate liver fibrosis in mice and inhibit hepatic stellate cell activation by secreting soluble factors.Stem cell research & therapy · 2025Article
- Glycoengineered extracellular vesicles released from antibacterial hydrogel facilitate diabetic wound healing by promoting angiogenesis.Journal of extracellular vesicles · 2024Article
- Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges.Signal transduction and targeted therapy · 2024Review
- Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease.Stem cell research & therapy · 2022Review
- N-Glycosylation and Inflammation; the Not-So-Sweet Relation.Frontiers in immunology · 2022Review
- Mesenchymal stem cell therapy for ischemic stroke: Novel insight into the crosstalk with immune cells.Frontiers in neurology · 2022Review
- CD44 Glycosylation as a Therapeutic Target in Oncology.Frontiers in oncology · 2022Review
- Mesenchymal stem cell therapy for ischemic stroke: A look into treatment mechanism and therapeutic potential.Journal of neurology · 2021Review
- CD44 fucosylation on bone marrow-derived mesenchymal stem cells enhances homing and promotes enteric nervous system remodeling in diabetic mice.Cell & bioscience · 2021Article
- A Novel Spindle Cell Population in a Case of Primary Osteoma Cutis With GNAS Mutation.The American Journal of dermatopathology · 2020Article
- Exofucosylation of Adipose Mesenchymal Stromal Cells Alters Their Secretome Profile.Frontiers in cell and developmental biology · 2020Article
- Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.Frontiers in immunology · 2019Article
- [The effects of CD44 fucosylation on fluid adhesion force of rabbit bone marrow mesenchymal stem cells].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2018Article
- The First Step in Adoptive Cell Immunotherapeutics: Assuring Cell Delivery via Glycoengineering.Frontiers in immunology · 2018Article
- Molecular Mechanisms of Transdifferentiation of Adipose-Derived Stem Cells into Neural Cells: Current Status and Perspectives.Stem cells international · 2018Review
- Multiple Roles of Glycans in Hematological Malignancies.Frontiers in oncology · 2018Review
- Post-surgery fluids promote transition of cancer stem cell-to-endothelial and AKT/mTOR activity, contributing to relapse of giant cell tumors of bone.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
The clinical effectiveness of systemically administered human mesenchymal stem cells (hMSCs) depends on their capacity to engage vascular endothelium. hMSCs derived from bone marrow (BM-hMSCs) natively lack endothelial binding capacity, but express a CD44 glycovariant containing N-linked sialyllactosamines that can be α(1,3)-fucosylated using fucosyltransferase-VI (FTVI) to enforce sLe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.